email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2641-1687

Journal of Urology & Nephrology Studies

Mini Review(ISSN: 2641-1687)

Prevalence and Risk Factors of Post-Transplantation Diabetes Mellitus in Patients after Kidney Allotransplantation in Moscow

Volume 1 - Issue 2

Novikova Maria*, AllazovaSona, Kotenko Oleg and Shilov Eugene

  • Author Information Open or Close
    • PhD, Department of nephrology, First Moscow State Medical University (Sechenov University),Russia

    *Corresponding author: Novikova Maria, PhD, Department of nephrology, First Moscow State Medical University (Sechenov University), Russia, Moscow, 11/4 Rossolimo str

Received: July 05, 2018;;   Published: July 11, 2018

DOI: 10.32474/JUNS.2018.01.000108

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


Purpose: To find out the prevalence, and the risk factors conducive to the development of post-transplantation diabetes mellitus (PTDM) after kidney allotransplantation (KAT).

Methods: The medical histories of 146 recipients of kidney allotransplants received between 1989 and 2014 were reviewed in retrospect. Diabetes mellitus diagnosed before KAT was a criterion for exclusion from the study. Analysed as risk factors were: sex, age, KAT time, and the use of glycocorticoids (GCs), tacrolimus (Tc), and/or cyclosporine A (CcA). The veritability of their influence was assessed using the step-wise linear regression analysis method.

Results: The recipients’ average age was 42.9 +/- 20.2 (х±σ) years at the time of the study. PTDM prevalence in the general group was 21.9% (n=32). Age and the use of calcineurin inhibitors (CNIs) and GCs had the greatest impact on PTDM development (р=0,01).

Keywords: Post-Transplantation Diabetes Mellitus; Kidney Allotransplantation; Glycocorticoids; Calcineurin Inhibitors; Tacrolimus; Cyclosporine

Abbrevations: KAT: Kidney Allotransplantation; PTDM:Post-Transplantation Diabetes Mellitus; GCs: Glycocorticoids; Tc: Tacrolimus; CcA:Cyclosporine A; CNIs: Calcineurin Inhibitors; NODAT: New Onset Diabetes After Transplantation; IGT: Impaired Glucose Tolerance; WHO: World Health Organisation; ADA:American Diabetes Association

Abstract| Introduction| Conclusion| References|